Impact of hypertension on vascular remodeling in patients with psoriatic arthritis

Journal of Human Hypertension

Volumn 28, Issue 2, 2014, Pages 105-110

  Puato, M ^a   Ramonda, R ^a   Doria, A ^a   Rattazzi, M ^b   Faggin, E ^a   Balbi, G ^a   Zanon, M ^a   Zanardo, M ^a   Tirrito, C ^a   Lorenzin, M ^a   Modesti, V ^a   Plebani, M ^a   Zaninotto, M ^a   Punzi, L ^a   Pauletto, P ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b OSPEDALE CA FONCELLO   (Italy)

Author keywords

Carotid ultrasound; Flow mediated dilation; Inflammation; Osteoprotegerin; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL INJURY; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MALE; PSORIATIC ARTHRITIS;

ADULT; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 84891867690     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.62     Document Type: Article

References (33)

1. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112(21): 3337-3347.
2. Doria A, Sherer Y, Meroni PL, Shoenfeld Y. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 2005; 31(2): 355-362,viii.
3. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54(8): 2665-2673.
4. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57(6): 1074-1080.
5. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008; 35(5): 877-882.
6. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011; 31(3): 705-712.
7. Troitzsch P, Paulista Markus MR, Dorr M, Felix SB, Junger M, Schminke U et al. Psoriasis is associated with increased intima-media thickness-the Study of Health in Pomerania (SHIP). Atherosclerosis 2012; 225(2): 486-490.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685-1695.
9. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/ RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4(6): 801-811.
10. Fadini GP, Rattazzi M, Matsumoto T, Asahara T, Khosla S. Emerging role of circulating calcifying cells in the bone-vascular axis. Circulation 2012; 125(22): 2772-2781.
11. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004; 18(4): 346-349.
12. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23(1): 7-17.
13. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64(Suppl 2:ii): 49-54.
14. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007; 25(9): 1751-1762.
15. Puato M, Palatini P, Zanardo M, Dorigatti F, Tirrito C, Rattazzi M et al. Increase in carotid intima-media thickness in grade I hypertensive subjects: white-coat versus sustained hypertension. Hypertension 2008; 51(5): 1300-1305.
16. Gemignani V, Faita F, Ghiadoni L, Poggianti E, Demi M. A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images. IEEE Trans Med Imaging 2007; 26(3): 393-404.
17. Ghiadoni L, Faita F, Salvetti M, Cordiano C, Biggi A, Puato M et al. Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens 2012; 30(7): 1399-1405.
18. Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev. 2011; 10(12): 773-778.
19. Riccioni G, Back M, Capra V. Leukotrienes and atherosclerosis. Curr Drug Targets. 2010; 11(7): 882-887.
20. Iversen L, Kragballe K, Ziboh VA. Significance of leukotriene-A4 hydrolase in the pathogenesis of psoriasis. Skin Pharmacol 1997; 10(4): 169-177.
21. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57(2): 287-293.
22. Pauletto P, Palatini P, Da Ros S, Pagliara V, Santipolo N, Baccillieri S et al. Factors underlying the increase in carotid intima-media thickness in borderline hypertensives. Arterioscler Thromb Vasc Biol 1999; 19(5): 1231-1237.
23. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009; 157(4): 527-536.
24. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middleaged men. Eur Heart J. 2002; 23(5): 376-383.
25. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101(18): 2149-2153.
26. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009; 116(3): 219-230.
27. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L et al. Relation between serum osteoprotegerin and carotid intima media thickness in a general population-the Tromso Study. J Thromb Haemost 2010; 8(10): 2133-2139.
28. Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007; 195(2): e135-e141.
29. Chandran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010; 49(7): 1399-1405.
30. Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006; 24(1 Suppl 40): S72-S78.
31. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204(2): 714-723.
32. Ovchinnikova O, Gylfe A, Bailey L, Nordstrom A, Rudling M, Jung C et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler Thromb Vasc Biol 2009; 29(10): 1478-1480.
33. Puato M, Faggin E, Rattazzi M, Paterni M, Kozakova M, Palombo C et al. In vivo noninvasive identification of cell composition of intimal lesions: a combined approach with ultrasonography and immunocytochemistry. J Vasc Surg 2003; 38(6): 1390-1395.